tiprankstipranks
Organon’s VTAMA Cream FDA Review Extended to 2025
Company Announcements

Organon’s VTAMA Cream FDA Review Extended to 2025

Stay Ahead of the Market:

The latest update is out from Organon ( (OGN) ).

Organon & Co. announced that the FDA has extended the review date for VTAMA® cream, used for treating atopic dermatitis, to March 12, 2025, without raising safety concerns. This extension impacts the company’s financial outlook for 2025, with expected revenue contributions and potential effects on earnings. Organon remains confident in the cream’s efficacy and is committed to providing the FDA with necessary information for approval.

See more data about OGN stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles